对胶质母细胞瘤进行表观遗传学重编程以克服化疗耐药性

IF 28.2 1区医学 Q1 CLINICAL NEUROLOGY

Nature Reviews Neurology Pub Date : 2025-04-04 DOI:10.1038/s41582-025-01083-w

Heather Wood

引用次数: 0

摘要

研究人员开发了一种基于crispr - cas9的表观遗传编辑方法，使胶质母细胞瘤细胞对标准化疗药物敏感，并可以改善对这些药物产生耐药性的肿瘤的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Epigenetic reprogramming of glioblastoma to overcome chemotherapy resistance

Researchers have developed a CRISPR–Cas9-based epigenetic editing approach that sensitizes glioblastoma cells to standard chemotherapy drugs and could improve the treatment of tumours that have developed resistance to these drugs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Neurology 医学-临床神经学

CiteScore

29.90

自引率

0.80%

发文量

138

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Neurology aims to be the premier source of reviews and commentaries for the scientific and clinical communities we serve. We want to provide an unparalleled service to authors, referees, and readers, and we work hard to maximize the usefulness and impact of each article. The journal publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians working in the field of neurology. Our broad scope ensures that the work we publish reaches the widest possible audience. Our articles are authoritative, accessible, and enhanced with clearly understandable figures, tables, and other display items. This page gives more detail about the aims and scope of the journal.